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The inherited mechanobullous disease, dystrophic epi-
dermolysis bullosa, is caused by type VII collagen gene
(COL7A1) mutations. We studied six unrelated patients
with a distinct clinical subtype of this disease, epi-
dermolysis bullosa pruriginosa, characterized by
pruritus, excoriated prurigo nodules, and skin fragility.
Mutation analysis using polymerase chain reaction
amplification of genomic DNA, heteroduplex analysis
and direct nucleotide sequencing demonstrated patho-
genetic COL7A1 mutations in each case. Four patients
had a glycine substitution mutation on one COL7A1
allele (G1791E, G2242R, G2369S, and G2713R), a
Dystrophic epidermolysis bullosa (EB) is an inheritedskin fragility disorder associated with anchoringfibril abnormalities and sublamina densa blistering(Tidman and Eady, 1985; Burgeson, 1993).Mutations in COL7A1 give rise to both autosomal
dominant and autosomal recessive forms of this disease (Christiano
and Uitto, 1996; Uitto, 1997). In dominant dystrophic EB,
mutations usually comprise glycine substitutions in the collagenous
triple helical domain of type VII collagen (Christiano et al, 1994;
1996a; Kon et al, 1997a, b), whereas autosomal recessive mutations
are more diverse in nature, including premature termination
codon mutations, mis-sense mutations, splicing mutations, delayed
termination codons, and silent glycine substitutions (Christiano
et al, 1996b; Hovnanian et al, 1997).
EB pruriginosa is a distinct clinical subtype of dystrophic EB in
which skin fragility, blistering, and scar formation is associated
with intense pruritus, nodular prurigo-like lichenified lesions,
nail dystrophy, and the variable presence of albopapuloid lesions
(McGrath et al, 1994; Cambiaghi et al, 1997). The onset of these
clinical features may be evident in early childhood, but in some
cases is delayed until the second or third decade of life. Autosomal
dominant, autosomal recessive, and sporadic inheritance patterns
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fifth was a compound heterozygote for a splice site
mutation (5532 F 1G-to-A) and a single base pair
deletion (7786delG), and a sixth patient was hetero-
zygous for an out-of-frame deletion mutation
(6863del16). This study shows that the molecular
pathology in patients with the distinctive clinical
features of epidermolysis bullosa pruriginosa is hetero-
geneous and suggests that other factors, in addition to
the inherent COL7A1 mutation(s), may be responsible
for an epidermolysis bullosa pruriginosa phenotype.
Key words: basement membrane zone, genetic blistering skin
disease, pruritus. J Invest Dermatol 112:984–987, 1999
have all been described in this disease (McGrath et al, 1994).
Recently, a glycine substitution in the triple helix of COL7A1,
G2242R, was reported in a Taiwanese pedigree with autosomal
dominant EB pruriginosa, representing the first mutation in this
subtype of EB (Lee et al, 1997).
In this study, we undertook mutation analysis of COL7A1 in
six unrelated patients with EB pruriginosa to determine whether
specific COL7A1 genotypes might underlie the striking clinical
manifestations of this form of dystrophic EB.
MATERIALS AND METHODS
Patients Patient 1, a 34 y old Caucasian British male, had skin fragility,
pruritus, nodular prurigo-like lesions, and nail dystrophy from the age of
7 y. His father also had mild blistering and excoriations consistent with
autosomal dominant inheritance. Patient 2, a Caucasian British female aged
40 y, had onset of typical EB pruriginosa features from infancy and no
family history of skin disease. Patient 3, who has been described previously
(McGrath et al, 1994), also with sporadic disease, was a 40 y old male of
Pakistani origin with prominent hypertrophic lichenified scarring and other
features of EB pruriginosa from the age of 17 y. Patient 4, a Caucasian
British female aged 34 y, had pruritic, lichenoid plaques with milia from
age 29 y. Her father had mild toenail dystrophy and a nephew had localized
trauma-induced blistering with scarring on his knees. Patient 5, a 13 y old
Caucasian British female, with no family history of skin disease, had
widespread linear prurigo lesions on her limbs, skin fragility, pruritus, and
nail involvement starting in infancy. Patient 6, a Hispanic Mexican male
aged 38 y, developed features of EB pruriginosa from 11 y, and had a five-
generation family history of disease with autosomal dominant transmission.
Further details of this pedigree have been described elsewhere (Cserhalmi-
Friedman et al, 1998). Electron microscopy and immunohistochemistry
of nonlesional skin was performed in three of six cases (patients 1, 3, and
4) and showed subtle alterations in anchoring fibril morphology with
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Table I. Mutation analysis reveals allelic heterogeneity for
COL7A1 mutations in epidermolysis bullosa pruriginosa
Patient Inheritance Position Mutation Verification
1 Dominant Exon 85 G2242R SacIa
2 Not knownb Exon 61 G1791E BlpI
3 Not knownc Exon 93 G2369S HphI
4 Dominant Exon 110 G2713R Eco01091
5 Recessive Intron 64 5532 1 1G-to-A TaiI
(de novo)
Exon 104 7786delG BsaJI
6 Dominant Exon 87 6863del16 sequencing
aSacI restriction digest using modified exon 85 primer (Lee et al, 1997).
bMutation excluded from maternal DNA, but paternal DNA unavailable for study.
cDNA from other family members not available for study.
occasional foci of sublamina densa cleavage, and normal or near-normal
expression of type VII collagen in all three cases.
Mutation analysis Genomic DNA was extracted from peripheral blood
lymphocytes of the six patients under study and family members where
available by standard methods (Sambrook et al, 1989), and used as a
template for polymerase chain reaction (PCR) amplification of COL7A1
using oligonucleotide primer pairs spanning all 118 exons of the gene and
PCR conditions described previously (GenBank numbers L02870, L23982)
(Christiano et al, 1997). In addition, a mismatch PCR method was used
to create an artificial SacI restriction site for screening exon 85 PCR
products for the mutation G2242R as described by Lee et al, 1997. Five
microliter aliquots of PCR products were analyzed by 2% agarose gel
electrophoresis then 3–8 µl of products were prepared for heteroduplex
analysis using conformation-sensitive gel electrophoresis (Ganguly et al,
1993). PCR products demonstrating altered electrophoretic mobility under-
went direct nucleotide sequencing in an ABI 310 genetic analyzer (Perkin
Elmer, Warrington, U.K.), and mutations were confirmed by restriction
endonuclease digestion, performed according to the manufacturer’s recom-
mendations (New England BioLabs, Hitchin, U.K.). Mutations detected
were excluded from 100 normal chromosomes using restriction enzyme
analysis or direct nucleotide sequencing.
RESULTS AND DISCUSSION
The pathogenetic mutations in COL7A1 identified in the six cases
are summarized in Table I.
Initial PCR of exon 85 using modified primers to create an
artificial restriction site for SacI (Lee et al, 1997) revealed the
presence of G2242R on one COL7A1 allele in patient 1 but not
in any of the other EB pruriginosa patients. This G-to-A transition,
which converts a glycine residue (GGG) to an arginine (AGG),
was confirmed in the patient and his father by direct nucleotide
sequencing. The mutation was not detected in the patient’s clinically
unaffected mother or daughter. In the remaining five patients,
mutation analysis of COL7A1 identified different mutations in each
case. Patients 2–4 had previously undescribed glycine substitution
mutations. The glycine substitutions in cases 2 and 3 were thought
to be de novo dominant mutations, although a recessive mode of
inheritance with failure to detect the second mutation on hetero-
duplex analysis could not be ruled out. In patient 2, the glycine
substitution arose from a G-to-A transition at nucleotide position
5372 in exon 61, converting a glycine residue (GGG) to glutamic
acid (GAG), G1791E. This mutation was not present in DNA
from the patient’s clinically unaffected mother, but paternal DNA
was not available for analysis. In patient 3, a G-to-A transition at
nucleotide position 7105 in exon 93, converting a glycine (GGT)
to serine (AGT), G2369S, was identified. DNA was not available
from parents or other family members to assess the inheritance of
this mutation. In patient 4, a G-to-C transversion at nucleotide
position 8137 in exon 110 was delineated, resulting in the conver-
sion of a glycine (GGC) to arginine (CGC), G2713R. This glycine
substitution was also identified in patient 49s father, two seemingly
clinically unaffected older siblings (no blisters, scars or nail dys-
trophy), and the clinically affected child of one of these siblings.
Mutation analysis in patient 5, with no family history of EB,
revealed compound heterozygosity for a paternally inherited single
base pair deletion mutation in exon 104, 7786delG, causing a shift
in the reading frame and a premature termination codon in exon
106, and a splice site mutation at the 59 donor consensus sequence
at the first nucleotide of intron 64, 5532 1 1G-to-A. The latter
mutation was not identified in parental DNA and had therefore
arisen as a de novo event. In patient 6, with autosomal dominant
disease, direct nucleotide sequencing of the exon 87 PCR product
revealed heterozygosity for a 16 bp deletion mutation, 6863del16.
This mutation was also present in the patient’s 10 y old daughter
with mild EB pruriginosa features. Other studies have shown that
this mutation results in in-frame exon skipping of exon 87, which
consists of 69 bp, rather than a frameshift and downstream premature
termination codon (Cserhalmi-Friedman et al, 1998). This phenom-
enon has also been described for other autosomal dominant deletion
mutations in COL7A1 (Sakuntabhai et al, 1998). Confirmatory
restriction endonuclease digestions for the mutations in patients
1–5, and direct nucleotide sequencing of exon 87 in patient 6, are
shown in Fig 1. Apart from the 7786delG mutation present on
one allele of patient 5 with recessive EB pruriginosa, none of the
mutations delineated in this study have been found in other patients
with nonpruriginosa variants of dystrophic EB. In addition, although
in-frame exon skipping in combination with a premature termina-
tion codon has been described in recessive dystrophic EB (Christiano
et al, 1996b), the particular combination of 5532 1 1G-to-A
and 7786delG has not been reported previously. One possible
consequence of this splice site mutation could be in-frame exon
skipping (Christiano et al, 1996b). Whereas this might be predicted
to cause less dominant negative interference when inherited in
trans with a premature termination codon rather than a wild-type
second allele, the splice variant may also compromise type VII
collagen processing, secretion, and anchoring fibril assembly. Unfor-
tunately, the precise consequences of this mutation could not be
determined as a skin biopsy was not available from patient 5. All
the mutations delineated in this study are illustrated in Fig 2,
which also shows all previously described mutations in dominant
dystrophic EB.
Four of our cases studied had glycine substitution mutations,
however, there was no consistency between the position of the
mutation in the triple helix (exons 61, 85, 93, and 110), nor the
resulting amino acid change (glutamic acid, arginine, or serine). Of
interest, a glycine to aspartic acid substitution has been described
previously at amino acid position 2713, G2713D, in nonpruriginosa
dominant dystrophic EB (Rouan et al, 1998). This is in contrast to
the pruriginosa phenotype in patient 4, in whom a different glycine
substitution, converting to arginine, was identified at this same
position. The presence of this mutation in the patient’s father and
nephew, with nonpruriginosa features of dominant dystrophic EB,
and her phenotypically normal siblings, however, suggests that,
whereas the nature of the substituted amino acid may be relevant
to the resulting phenotype, additional factors may also be implicated.
Although intrafamilial variability in dominant dystrophic EB is well
recognized, it appears to be particularly evident in EB pruriginosa,
as demonstrated in the family of patient 4. Clearly, therefore,
accurate genetic counseling for this condition must involve screen-
ing of genomic DNA of all family members and must not be based
on clinical examination alone, even if careful assessment is made
of subtle signs such as minor nail dystrophy.
Figure 2 demonstrates that glycine substitution mutations giving
rise to dominant dystrophic EB are distributed across the triple
helix with clustering in exon 73 close to the noncollagenous hinge
region. Nevertheless, some evidence for clustering of EB pruriginosa
mutations in a different part of COL7A1 has been suggested by
Tamai et al1 who identified glycine substitutions in exon 85. This
was not corroborated by our series, however.
In view of the heterogeneous nature of these mutations, we
assessed other indices that might account for the pruritus in our
cases. Serum IgE levels were measured in two of the patients
studied and in a further seven with EB pruriginosa, and found to
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Figure 1. Verification of the EB
pruriginosa mutations is shown by
restriction endonuclease digestion
(patients 1–5 and control, C) or direct
nucleotide sequencing (patient 6).
(a) In patient 1, SacI digestion of exon 85
mismatch PCR products cuts the 207 bp
PCR product into 187 bp and 20 bp
fragments on the mutant G2242R allele.
(b) G1791E creates a BlpI restriction
endonuclease site. In patient 2, the 506 bp
PCR product is digested into additional
bands of 381 bp and smaller fragments.
(c) In patient 3, G2369S abolishes a HphI
restriction site. Control PCR product is
cut into fragments of 197 bp, 55 bp, and
59 bp, whereas patient 3 has an additional
undigested 252 bp band. (d) The control
PCR product spanning exon 110 is digested
by Eco01091 into fragments of sizes 104 bp,
97 bp, and , 70 bp. In patient 4, G2713R
abolishes an Eco01091 restriction site,
resulting in an additional undigested band
of 128 bp (e) 5532 1 1G-to-A abolishes a
TaiI restriction site. Control exon 63/64
PCR product is digested into 247 bp and
smaller fragments, whereas patient 5 has an
undigested 312 bp band corresponding to
the mutant allele. (f) 7786delG abolishes a
BsaJI cut site. The control 512 bp exon
103/104 PCR product is digested into
, 60 bp fragments, but patient 5 has
an additional band of 120 bp. (g) Direct
nucleotide sequencing of exon 87 PCR
products from patient 6 reveals a 16 bp
deletion, 6863del16, on one allele. Wild-
type (top) and mutant (bottom) sequences
are shown from subcloned PCR products.
(h) Gel electrophoresis of the 404 bp exon
86/87 PCR products shows a second band
of 388 bp in patient 6 corresponding to
the mutant allele (3% Nu-Sieve agarose gel;
Flowgen, Litchfield, U.K.). M 5 ΦX174
molecular weight marker.
be elevated in seven cases (112→1000 kU per liter; normal range
0–81 kU per liter), and to at least three times the upper limit of
normal in three of these patients. Of these seven patients, one had
a personal history of eczema, and two had family, but not personal,
histories of atopy. Serum IgE levels were also found to be elevated
in two of six control patients with nonpruriginosa dystrophic EB
who were not known to be atopic. Clearly, an elevated IgE does
not specifically account for a pruriginosa phenotype and additional
potential predisposing factors for atopy, such as alterations in the β
subunit of the high-affinity IgE receptor (Cox et al, 1998) or
cytokine polymorphisms (Mitsuyasu et al, 1998) may be implicated.
The described clinical improvement of EB pruriginosa with cyclo-
sporine A is supportive of additional immune-mediated factors in
the pathogenesis of this disease (Yamasaki et al, 1997). There was
no evidence for other causes of itching in the patients studied, such
as thyroid dysfunction or low ferritin levels. The pathophysiology
of itch is poorly understood, however, and other potential modifying
factors remain to be elucidated.
The reasons for the frequently delayed onset of clinical features
in EB pruriginosa remains unclear. The position of mutations in
the type VII collagen triple helix may be significant, with most
glycine substitution mutations in nonpruriginosa dominant dys-
trophic EB clustered around exon 73. Mutations in other regions
of the triple helix, as observed in our patients, may cause less
dominant negative interference and only result in clinical disease
when combined with additional inherited or acquired predisposing
factors. Similarly, the position of a glycine substitution mutation
may influence the susceptibility of type VII collagen to secondary
proteolysis, with potential for differences in breakdown products
triggering an inflammatory cascade in the patient’s skin.
This study demonstrates the molecular heterogeneity underlying
EB pruriginosa, with glycine substitution mutations, a deletion
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Figure 2. Database of mutations in type VII collagen resulting in
dominant dystrophic EB and EB pruriginosa. Mutations delineated
in this study are shown in bold. G2040S (Christiano et al, 1994); G2043R
(Christiano et al, 1995a; Cserhalmi-Friedman et al, 1997; Winberg et al,
1997); G2623C (Christiano et al, 1995b); 6900 1 4G-to-A;2 G1557R and
G2055E (Christiano et al, 1996a); G2003R (Christiano et al, 1996c);
G2079E (Kon et al, 1997a); G2034R, G2076D, G2079R, and G2207R
(Kon et al, 1997b); G2242R (Lee et al, 1997); G2006D, G2015E, and
G2034R (Hammami-Hauasli et al, 1998a); G2034W, G2040V, G2043R,
G2064R, G2079R, and G2713D (Rouan et al, 1998); G2215E (Hammami-
Hauasli et al, 1998b); 6081del28 and 6847del27 (Sakuntabhai et al, 1998);
G2239D and G2242E;1 G2037E.3
mutation causing in-frame exon skipping, and compound hetero-
zygosity for a frameshift mutation and a splice site mutation all
giving rise to this subtype of dystrophic EB. This mutational
diversity, the variability of onset of clinical features, and the absence
of phenotype in the siblings of patient 4, lends support to a possible
role for other, as yet undefined, factors in the pathogenesis of EB
pruriginosa.
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